Tamoxifen for breast cancer chemoprevention: Low uptake by high-risk women after evaluation of a breast lump

Annals of Family Medicine

Volumn 3, Issue 3, 2005, Pages 242-247

  Taylor, Rebecca ^a,c   Taguchi, Kenneth ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

Anticarcinogenic agents; BCPT trial; Breast neoplasms; Chemoprevention; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST LESION; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG UPTAKE; DRUG UTILIZATION; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HIGH RISK PATIENT; HOT FLUSH; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PRESCRIPTION; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STROKE; THROMBOEMBOLISM; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; TAMOXIFEN;

EID: 20444395822     PISSN: 15441709     EISSN: None     Source Type: Journal    
DOI: 10.1370/afm.284     Document Type: Article

References (30)

1. Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
2. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer; an instance of fingerpost. J Natl Cancer Inst. 1999;91:1809-1819.
3. Reynolds T. Tamoxifen debate hinges on whose risk is high enough. J Natl Cancer Inst. 1998;90:1428-1430.
4. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;B1:1879-1886.
5. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998;352:93-97.
6. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
7. Goel V. Tamoxifen and breast cancer prevention: What should you tell your patients? CMAJ. 1998;158:1615-1617.
8. Margolese RG. How do we interpret the results of the Breast Cancer Prevention Trial? CMAJ. 1998;158:1613-1614.
9. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? (commentary) Lancet. 1998;352:80-81.
10. Gail MH, Constantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for prevention. J Natl Cancer Inst. 1999;91:1829-1646.
11. Daly M, Seay J, Balshem A, Lerman C, Engstrom P. Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 1992;1:413-1416.
12. Yeomans-Kinney A, Vernon SW, Frankowski RF, Weber DM, Bitsura JM, Vogel VG. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer. 1995;76:46-56.
13. Port ER, Montgomery LL, Heert AS, Borgen PI. Patient reluctance towards tamoxifen use for breast cancer primary prevention. Ann Surg Onc 2001;8:580-585.
14. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11:1-47.
15. McNagny SE, Jacobsen TA. Use of postmenopausal hormone replacement therapy by African American women. The importance of physician discussion. Arch Intern Med. 1997;157:1337-1342.
16. Walsh JM, Brown JS, Rubin S, Kagawa M, Grady D. Post menopausal hormone therapy: factors influencing women's decision making. Menopause. 1997;4:39-45.
17. Newton KM, Lacroix AZ, Leveille SG, Rutter C, Keenan NL, Anderson LA. The physician's role in women's decision making about hormone replacement therapy. Obstet Gynecol. 1998;92:580-584.
18. Skinner CS, Stretcher VJ, Hospers H. Physicians' recommendations for mammography: do tailored messages make a difference? Am J Public Health. 1994;84:43-49.
19. Yeomans Kinney a, Richards C, Vernon S, Vogel V. The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med. 1998;27:713-719.
20. Vogel V. Breast cancer prevention: a review of current evidence. CA Cancer J Clin. 2000;50:156-170.
21. Constantino JP, Gail MH, Pee D et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541-1548.
22. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individualized breast cancer risk. J Natl Cancer Inst. 1994;86:600-607.
23. IBIS Investigators. First results from the International Breast Cancer Intervention Study: a randomised prevention trial. Lancet. 2002;360:817-824.
24. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin. 1999;49:159-177.
25. Brown P, Lippman S. Chemoprevention of breast cancer. Breast Cancer Res Treat. 2000;62:1-17.
26. King MC, Wieand S, Hale K, Lee M et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;28B:2251-2256.
27. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218-221.
28. Cummings SR, Eckert S, Lippman M, et al. The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189-2197.
29. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125-134.
30. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-532.